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Introduction
Schnitzler’s syndrome (SchS) is an autoinflammatory dis-
order, characterized by chronic urticaria, fever, gammopa-
thy and bone pain. The pathophysiology is unknown, but
the effectiveness of interleukin-1 (IL-1) inhibition provides
a clue.
Objectives
Our aim was to study the effect of IL-1b inhibition on
inflammatory responses in vivo and ex vivo during a trial
of the long-acting anti-IL-1b antibody canakinumab in
SchS.
Methods
Eight patients with SchS received monthly injections with
150mg canakinumab s.c. for six months. Blood was drawn
at several time points for measurement of inflammation
markers and isolation of peripheral blood mononuclear
cells (PBMCs), which were stimulated with lipopolysacchar-
ide (LPS). Skin biopsies of urticae and clinically uninvolved
skin were taken for mRNA, histology and keratinocyte cul-
tures. Submerged keratinocytes were stimulated with sev-
eral cytokines and patient and control serum. All data were
compared to results of healthy controls.
Results
IL-1b inhibition was highly effective in SchS. IL-6 protein
concentration in lysates of freshly isolated PBMCs corre-
lated with disease activity. Stimulation of PBMCs with
0,1 ng/ml LPS induced more IL-6 and IL-1b production
in SchS PBMCs than in controls. In lesional epidermis,
mRNA and protein expression levels of several antimi-
crobial proteins were elevated. In primary human kerati-
nocytes, poly:IC, IL-1b, IL-17 and interferon gamma
induced mRNA expression levels of several antimicrobial
proteins and cytokines to a similar extent in patient and
control cells.
Conclusion
Clinical efficacy of IL-1b inhibition in patients with SchS is
associated with in vivo and ex vivo suppression of inflam-
mation. Our data underscore that IL-1b plays a pivotal
role in this disease. Also, we show strong upregulation of
antimicrobial proteins in the epidermis of these neutrophi-
lic urticaria, and that these proteins can be induced in pri-
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